Phase II study of E7070 in patients with metastatic melanoma
Smyth, JF × Aamdal, S Awada, A Dittrich, C Caponigro, F Schöffski, Patrick Gore, M Lesimple, T Djurasinovic, N Baron, B Ravic, M Fumoleau, P Punt, CJA #
Kluwer Academic Publishers
Annals of Oncology vol:16 issue:1 pages:158-161
E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma.